Acetaminophen Patent Expiration

Acetaminophen was first introduced by Polymedica Industries Inc in its drug Neopap on Approved Prior to Jan 1, 1982. Other drugs containing Acetaminophen are Acephen, Acetaminophen, Injectapap, Ofirmev, Infants' Feverall, Tylenol. 32 different companies have introduced drugs containing Acetaminophen.


Acetaminophen Patents

Given below is the list of patents protecting Acetaminophen, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ofirmev US9399012

(Pediatric)

Reduced dose intravenous acetaminophen Mar 11, 2032 Mallinckrodt Hosp
Ofirmev US9399012 Reduced dose intravenous acetaminophen Sep 11, 2031 Mallinckrodt Hosp
Acetaminophen US8741959 Paracetamol for parenteral administration Apr 19, 2030 Fresenius Kabi Usa
Ofirmev US10383834

(Pediatric)

Reduced Dose Intravenous Acetaminophen May 13, 2029 Mallinckrodt Hosp
Ofirmev US9610265

(Pediatric)

Reduced dose intravenous acetaminophen May 13, 2029 Mallinckrodt Hosp
Ofirmev US9987238

(Pediatric)

Reduced dose intravenous acetaminophen May 13, 2029 Mallinckrodt Hosp
Ofirmev US10383834 Reduced dose intravenous acetaminophen Nov 13, 2028 Mallinckrodt Hosp
Ofirmev US9610265 Reduced dose intravenous acetaminophen Nov 13, 2028 Mallinckrodt Hosp
Ofirmev US9987238 Reduced dose intravenous acetaminophen Nov 13, 2028 Mallinckrodt Hosp
Ofirmev US6992218

(Pediatric)

Method for obtaining aqueous formulations of oxidation-sensitive active principles Dec 06, 2021

(Expired)

Mallinckrodt Hosp
Ofirmev US6992218 Method for obtaining aqueous formulations of oxidation-sensitive active principles Jun 06, 2021

(Expired)

Mallinckrodt Hosp
Ofirmev US6028222

(Pediatric)

Stable liquid paracetamol compositions, and method for preparing same Feb 05, 2018

(Expired)

Mallinckrodt Hosp
Ofirmev US6028222 Stable liquid paracetamol compositions, and method for preparing same Aug 05, 2017

(Expired)

Mallinckrodt Hosp



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Acetaminophen's patents.

Given below is the list recent legal activities going on the following patents of Acetaminophen.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 03 Dec, 2025 US8741959
Payment of Maintenance Fee, 8th Year, Large Entity 03 Dec, 2021 US8741959
Payment of Maintenance Fee, 4th Year, Large Entity 23 Nov, 2017 US8741959
Patent Issue Date Used in PTA Calculation 03 Jun, 2014 US8741959
Recordation of Patent Grant Mailed 03 Jun, 2014 US8741959
Email Notification 16 May, 2014 US8741959
Issue Notification Mailed 14 May, 2014 US8741959
Dispatch to FDC 05 May, 2014 US8741959
Application Is Considered Ready for Issue 05 May, 2014 US8741959
Issue Fee Payment Verified 24 Apr, 2014 US8741959


Acetaminophen's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Clinical Trials

Recent Clinical Trials on Acetaminophen:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Trial of Therapeutic Hypothermia in Patients With ARDS University of Maryland, Baltimore NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2
Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments University of British Columbia NA RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3
Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis The Cleveland Clinic NA RECRUITING
(Sep 1, 2026)
PHASE3
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL) Baylor College of Medicine NA RECRUITING
(Sep 1, 2026)
PHASE1
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants Hoffmann-La Roche NA RECRUITING
(Sep 1, 2026)
PHASE2
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) Baylor College of Medicine NA RECRUITING
(Sep 1, 2026)
PHASE1
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain AFT Pharmaceuticals, Ltd. NA RECRUITING
(Sep 1, 2026)
PHASE3
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE2
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3
Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma Dana-Farber Cancer Institute NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity Eli Lilly and Company NA RECRUITING
(Sep 1, 2026)
PHASE1
Post-Vasectomy Pain Study Columbia University NA RECRUITING
(Sep 1, 2026)
PHASE1
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Merck Sharp & Dohme LLC NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Aug 6, 2026)
PHASE2
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL Baylor College of Medicine NA COMPLETED
(Aug 1, 2026)
PHASE1
Paracetamol and Pharmacogenetic University Hospital, Clermont-Ferrand NA COMPLETED
(Aug 1, 2026)
PHASE1
Acetaminophen's Antinociceptive Effect When Associated With N-Acetylcysteneine University Hospital, Clermont-Ferrand NA COMPLETED
(Aug 1, 2026)
PHASE1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma Baylor College of Medicine NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1
Efficacy of Different Drugs to Control Post Root Canal Treatment Pain University of Khartoum NA COMPLETED
(Aug 1, 2026)
PHASE2
FIGHT-RP 1 Extension Study Johns Hopkins University NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas Baylor College of Medicine NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1
Opioid Analgesic Reduction Study Rutgers, The State University of New Jersey NA COMPLETED
(Aug 1, 2026)
PHASE3
Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants Mount Sinai Hospital, Canada NA RECRUITING
(Aug 1, 2026)
PHASE2
Therapies for Down Syndrome Regression Disorder University of Colorado, Denver NA COMPLETED
(Aug 1, 2026)
PHASE2
NSAID Use After Robotic Partial Nephrectomy University of Miami NA RECRUITING
(Aug 1, 2026)
PHASE2
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) Merck Sharp & Dohme LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) Merck Sharp & Dohme LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) Merck Sharp & Dohme LLC NA COMPLETED
(Aug 1, 2026)
PHASE1
Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy Brigham and Women's Hospital NA RECRUITING
(Aug 1, 2026)
PHASE2
Patient Controlled Administration of Liquid Acetaminophen Yale University NA COMPLETED
(Aug 1, 2026)
PHASE1
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Merck Sharp & Dohme LLC NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2
Oral Acetaminophen for Post-Op Pain Management in Bariatric Surgery Patients Rutgers, The State University of New Jersey NA COMPLETED
(Aug 1, 2026)
PHASE2
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) Merck Sharp & Dohme LLC NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2
NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome Brigham and Women's Hospital NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE1
Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI) Val Adams NA RECRUITING
(Aug 1, 2026)
PHASE2
A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant Novo Nordisk A/S NA RECRUITING
(Aug 1, 2026)
PHASE1
Maxigesic for Postoperative Pain Control After Laparoscopic or Robotic Gastrectomy Seoul National University Bundang Hospital NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
Buprenorphine for the Management of Pain in Children With Sickle Cell Disease Natasha Archer NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE1
Sac-TMT in Vaginal and Vulvar Cancers Latin American Cooperative Oncology Group NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Alliance for Clinical Trials in Oncology NA COMPLETED
(Jul 1, 2026)
PHASE3
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation Weill Medical College of Cornell University NA COMPLETED
(Jul 1, 2026)
PHASE2
Epidural Analgesia for Pancreatitis (Epipan Study) University Hospital, Clermont-Ferrand NA COMPLETED
(Jul 1, 2026)
PHASE3
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
T-Cell Therapy for Advanced Breast Cancer Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
A Study of Oxidative Pathways in MS Fatigue University of California, San Francisco NA COMPLETED
(Jul 1, 2026)
PHASE2
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) National Cancer Institute (NCI) NA COMPLETED
(Jul 1, 2026)
PHASE1
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Baylor College of Medicine NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis Hoffmann-La Roche NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy Hoffmann-La Roche NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Pediatric Brain Tumor Consortium NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Superficial Cervical Plexus Block and Quality of Recovery After Thyroidectomy Yale University NA COMPLETED
(Jul 1, 2026)
PHASE2
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas Baylor College of Medicine NA RECRUITING
(Jul 1, 2026)
PHASE1
Pain After Strabismus Surgery Ann & Robert H Lurie Children's Hospital of Chicago NA SUSPENDED
(Jul 1, 2026)
PHASE2
Optimizing Pain Treatment in Children On Mechanical Ventilation Weill Medical College of Cornell University NA RECRUITING
(Jul 1, 2026)
PHASE3
RADA16 for Adult Tonsillectomy Rutgers, The State University of New Jersey NA RECRUITING
(Jul 1, 2026)
PHASE3
R.E.C.K vs Exparel in Robotic Nephrectomy Wake Forest University Health Sciences NA RECRUITING
(Jul 1, 2026)
PHASE3
Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children Rutgers, The State University of New Jersey NA RECRUITING
(Jul 1, 2026)
PHASE2
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma Baylor College of Medicine NA RECRUITING
(Jul 1, 2026)
PHASE1
An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service University of California, San Francisco NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE3
Probiotic Supplements in Osteoarthritis Beni-Suef University NA COMPLETED
(Jul 1, 2026)
PHASE3
A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity Pfizer NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1
Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery Shanghai Huilun Pharmaceutical Co., Ltd. NA RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3
Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer Henan Cancer Hospital NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE1
Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Abdominal Surgery Shanghai Huilun Pharmaceutical Co., Ltd. NA RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3
The Anesthetic and Analgesic Effect of Adjunct Liposomal Bupivacaine in Periodontal Surgical Procedures The University of Texas Health Science Center at San Antonio NA COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2
Methoxyflurane Versus Usual Care for Non-Traumatic Pain in Emergency Departments University Hospital, Tours NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE3
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2
Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy University of Wisconsin, Madison NA COMPLETED
(Jun 1, 2026)
PHASE2
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Adrienne G. Waks NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2
Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial Washington University School of Medicine NA COMPLETED
(Jun 1, 2026)
PHASE2
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. Baylor College of Medicine NA RECRUITING
(Jun 1, 2026)
PHASE1
Comparison of an Inhaled Sedation Strategy to an Intravenous Sedation Strategy in Intensive Care Unit Patients Treated With Invasive Mechanical Ventilation University Hospital, Brest NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3
Reducing Opioid Use and Misuse After Wisdom Molar Extractions Rutgers, The State University of New Jersey NA SUSPENDED
(Jun 1, 2026)
PHASE2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone Stanford University NA RECRUITING
(Jun 1, 2026)
PHASE2
Oral N-acetylcysteine for Retinitis Pigmentosa Johns Hopkins University NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy Wake Forest University Health Sciences NA TERMINATED
(Jun 1, 2026)
PHASE2, PHASE3
Siplizumab for Sickle Cell Disease Transplant Columbia University NA TERMINATED
(Jun 1, 2026)
PHASE1, PHASE2
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. Masonic Cancer Center, University of Minnesota NA RECRUITING
(Jun 1, 2026)
PHASE2
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults Sanaria Inc. NA RECRUITING
(Jun 1, 2026)
PHASE1
Non-Narcotic Pain Control After ACL Reconstruction The Cleveland Clinic NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2
Jaw Muscle Pain Post Wisdom Molar Surgery Rutgers, The State University of New Jersey NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE2
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC Beijing Biotech NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2
Vaccination With Flt3L, Radiation, and Poly-ICLC Icahn School of Medicine at Mount Sinai NA COMPLETED
(May 1, 2026)
PHASE1, PHASE2
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1
Study of Post-Herniorrhaphy Non-opioid MMA Regimens Heron Therapeutics NA COMPLETED
(May 1, 2026)
PHASE3
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) Merck Sharp & Dohme LLC NA COMPLETED
(May 1, 2026)
PHASE2
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter M.D. Anderson Cancer Center NA TERMINATED
(May 1, 2026)
PHASE2
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus Hoffmann-La Roche NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3
Zonisamide Versus Topiramate in Migraine Kafrelsheikh University NA COMPLETED
(May 1, 2026)
PHASE3
Dexamethasone for Ureteral STent Symptoms (DUSTS) The Methodist Hospital Research Institute NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2
Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome Children's Hospital of Fudan University NA NOT YET RECRUITING
(May 1, 2026)
PHASE3
Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus University of South Alabama NA TERMINATED
(Apr 1, 2026)
PHASE2
Post-Op Pain Control for Prophylactic Intramedullary Nailing. St. Louis University NA RECRUITING
(Apr 1, 2026)
PHASE3
PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients Beth Israel Deaconess Medical Center NA COMPLETED
(Apr 1, 2026)
PHASE3
A Study of N-acetylcysteine in Patients With COVID-19 Infection Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2
MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer University of Wisconsin, Madison NA COMPLETED
(Apr 1, 2026)
PHASE1
A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain Johns Hopkins University NA COMPLETED
(Apr 1, 2026)
PHASE3
Herniorrhaphy for Postoperative Pain Cali Pharmaceuticals LLC NA COMPLETED
(Apr 1, 2026)
PHASE3
CPL-01 in the Management of Postoperative Pain After Bunionectomy Cali Pharmaceuticals LLC NA COMPLETED
(Apr 1, 2026)
PHASE3
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Johnson & Johnson Consumer Inc. (J&JCI) NA COMPLETED
(Apr 1, 2026)
PHASE3
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants Eli Lilly and Company NA COMPLETED
(Apr 1, 2026)
PHASE1
Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity University of South Alabama NA COMPLETED
(Apr 1, 2026)
PHASE1
Efficacy of Rifaximin With NAC in IBS-D Mark Pimentel, MD NA RECRUITING
(Apr 1, 2026)
PHASE2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects Fujian Shengdi Pharmaceutical Co., Ltd. NA COMPLETED
(Apr 1, 2026)
PHASE1
Opioid-Sparing Joint Replacement Emory University NA RECRUITING
(Apr 1, 2026)
PHASE3
Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen Wake Forest University Health Sciences NA RECRUITING
(Apr 1, 2026)
PHASE3
A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight Novo Nordisk A/S NA RECRUITING
(Apr 1, 2026)
PHASE1
Comparison of Acetaminophen With Aminophylline and Aminophylline With Dexamethasone for Prophylaxis of PDPH in Patients With History of PDPH. Sargodha Medical College NA COMPLETED
(Apr 1, 2026)
PHASE2
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis The Fourth Affiliated Hospital of Zhejiang University School of Medicine NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2
Endovenous Laser Ablation With 1940 nm Versus 1470 nm Kafrelsheikh University NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma University of Miami NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2
Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture Mayo Clinic NA RECRUITING
(Mar 1, 2026)
PHASE2
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma Benjamin T Diamond, MD NA RECRUITING
(Mar 1, 2026)
PHASE2
Evaluation of Pain Management After Surgery When Using Exparel in the Pediatric Population Texas Scottish Rite Hospital for Children NA RECRUITING
(Mar 1, 2026)
PHASE2
The SCOPE Trial: Sleep, Cognition, and Pain Bundle vs. ERAS-cardiac for Postoperative Delirium Beth Israel Deaconess Medical Center NA RECRUITING
(Mar 1, 2026)
PHASE3
Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain Contineum Therapeutics NA COMPLETED
(Mar 1, 2026)
PHASE1
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC Beijing Biotech NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) Beijing Biotech NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC Beijing Biotech NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2


Acetaminophen Generic API Manufacturers

Several generic applications have been filed for Acetaminophen. The first generic version for Acetaminophen was by Perrigo New York Inc and was approved on Dec 1, 1986. And the latest generic version is by Caplin Steriles Ltd and was approved on Dec 5, 2025.

Given below is the list of companies who have filed for Acetaminophen generic, along with the locations of their manufacturing plants worldwide.